Enhanced external counterpulsation for ischemic heart disease: a look behind the curtain. Exerc. Sport Sci. Rev., Vol. 40, No. 3, pp. 145Y152, 2012. Enhanced external counterpulsation (EECP) is a noninvasive treatment for patients with coronary artery disease who have angina pectoris that is refractory to pharmacotherapy and revascularization. The popular concept is that EECP may promote collateral development and improve myocardial perfusion. We hypothesize that improvements in peripheral arterial function are responsible for the clinical benefits of EECP. . 35 (POST) sessions of enhanced external counterpulsation and sham treatment. Data are presented as means T SEM (*P G 0.01 vs PRE; †P G 0.05 vs MID; ‡P G 0.05 vs sham). (Reprinted from (6).
INTRODUCTION
Enhanced external counterpulsation (EECP) is a noninvasive outpatient therapy, approved by the U.S. Food and Drug Administration in 1995, for the treatment of patients with coronary artery disease (CAD) and refractory angina pectoris who fail to respond to standard revascularization procedures and aggressive pharmacotherapy. Data from the International Patient Registry demonstrate that EECP effectively decreased angina episodes and nitrate usage and increased exercise tolerance in patients with refractory angina (2, 31) . The anti-ischemic benefits occur early and are sustained up to 5 yr in patients with a favorable initial response (15, 28) . However, the mechanisms by which EECP improves angina symptoms are not understood and remain controversial.
The popular hypothesis is that EECP promotes coronary collateral growth and improves myocardial perfusion. However, this understanding of EECP is a theory and remains unproven in randomized clinical trials. In an international trial (7 centers; 175 patients with chronic stable angina), EECP failed to elicit improved cardiac perfusion in 46% of study subjects (29) . In a recent U.S. trial (6 U.S. university hospitals; 37 patients with stable chronic angina), EECP failed to improve myocardial blood flow to and within ischemic regions of the myocardium (19) . However, despite negligible improvements in myocardial perfusion (i.e., oxygen supply), approximately 85% of patients enrolled in EECP clinical trials experience reduction in angina and improvement in exercise tolerance (2, 29) .
For the past 6 yr, we have studied the extracardiac vascular effects of EECP in patients with CAD and refractory angina. In contrast to previous studies, our line of research has focused on EECP-induced improvement in peripheral arterial function and decreased myocardial oxygen consumption (i.e., oxygen demand) versus improvement in coronary blood flow (i.e., oxygen supply). We hypothesized that hemodynamic shear stress, with each inflation/deflation cycle of the compressive EECP cuffs (11) , would improve endothelial function in peripheral muscular conduit arteries (5) , decrease arterial stiffness (6) , and thereby reduce myocardial oxygen demand and angina (6, 23) . We further hypothesized that EECP would elicit commensurate changes in endothelial-derived vasoactive agents, plasma inflammatory cytokines, and indices of oxidative damage (5, 7) . We speculated that these peripheral changes also beneficially influence the timing and amplitude of aortic reflected pressure waves, thereby reducing left ventricular (LV) wasted energy and myocardial oxygen demand (6, 21) .
The purpose of this review is to integrate a recent series of studies by the authors and others that identify the extracardiac mechanisms by which EECP decreases angina episodes and nitrate usage while improving exercise tolerance in patients with symptomatic CAD.
EVOLUTION OF COUNTERPULSATION
Counterpulsation as treatment for heart disease is not a new procedure. The concept of mechanically improving blood flow to the ischemic myocardium by increasing coronary perfusion can be traced back to the 1950s. Early research led to the development of the intra-aortic balloon pump (IABP). The IABP consists of an inflatable balloon catheter that is inserted into the femoral artery and advanced to the descending aorta. Rapid inflation of the balloon in diastole augments coronary artery perfusion. Modified and refined over the last 50 yr, this device remains a primary therapy for assisting the heart function of patients in cardiogenic shock. In the mid-1960s, Birtwell and others at Harvard developed a device for external counter pulsation (4) . It was a hydraulic system that pumped water in and out of cuffs applied to the lower extremities. Although cumbersome, there were obvious advantages of the ''Birtwell device.'' It was noninvasive and also increased venous return, thereby promoting cardiac output as it boosted coronary perfusion pressure. These early hydraulic devices reduced angina pectoris and increased survival rates of patients with acute myocardial infarction and cardiogenic shock. However, in the United States, external counter pulsation was eclipsed by the emergence of coronary artery bypass graft surgery (CABG) and angioplasty. In the 1970s, a more sophisticated external counter pulsation system was developed using pneumatic cuffs that inflated sequentially, rather than simultaneously as they had before ( Fig. 1 ). Although pneumatic cuffs vastly improved EECP cycling speed versus the hydraulic system, sequential inflation (distal to proximal) introduced the possibility that rapid venous return and increased right ventricular loading might have adverse consequences in patients with symptomatic heart failure (HF) secondary to systolic dysfunction. However, EECP has been shown to improve exercise tolerance, quality of life, and New York Heart Association classification in stable HF patients without adverse consequences (2, 28) .
During an EECP treatment session using the modern ''enhanced'' counterpulsation system, the patient lies on a padded table in which sets of electronically controlled inflation and deflation valves are located. These valves are connected to three pairs of pneumatic cuffs, wrapped around the calves, thighs, and buttocks. The cuffs are inflated sequentially to 300 mm Hg with compressed air from distal to proximal in early diastole and rapidly deflated at the onset of systole ( Fig. 1 ). Inflation and deflation of the cuffs are triggered by events in the cardiac cycle via microprocessor-interpreted electrocardiogram signals. A standard course of EECP treatment consists of 35 one-hour sessions over a 7-wk period.
INDICATIONS FOR EECP
A considerable segment of patients with CAD are not amenable to standard revascularization procedures, such as angioplasty and CABG, because of unsuitable coronary anatomy, multiple previous revascularization attempts, age, additional comorbid conditions, or patient preference. Such difficult cases require physicians to entertain other options. In the United States alone, there are more than 2.4 million patients with CAD not amenable to bypass or angioplasty (13) . For those patients in whom repeat (or initial) revascularization procedures are not appropriate, and in whom aggressive medical therapy fails to reduce angina pain, the search for additional therapeutic options continues. New treatment modalities, which are at various stages of clinical evaluation, include minimally invasive bypass surgery, spinal cord stimulation, transcutaneous electrical nerve stimulation, transmyocardial laser revascularization, stem cell therapy, and EECP. Of these modalities, EECP is the only truly noninvasive, atraumatic technique for which clinical anti-ischemic improvements have been shown. In the United States alone, approximately 650 centers currently are providing EECP therapy.
THERAPEUTIC TARGET OF EECP: THE CENTRAL HYPOTHESIS
The often postulated mechanism of action of EECP describes robust diastolic pressure augmentation during the rapid cuff inflation, analogous to IABP counterpulsation (18) . Indeed, acute coronary artery flow, determined by both Doppler and angiographic techniques, is increased during EECP, suggesting that external compression may serve as a potential mechanical assist device (18) .
Nonetheless, it remains unclear how diastolic augmentation could translate into the chronic anti-ischemic benefits of EECP. It is conceivable that diastolic augmentation and possible increased coronary shear forces could stimulate arteriogenesis, the maturation of epicardial vessels or opening of dormant collaterals, and/or angiogenesis, the formation of de novo vessels that perfuse the myocardium. However, this is a theory and has not been proven in humans, despite provocative evidence of improved myocardium perfusion in dogs (14) . Indeed, EECP researchers using surrogate measures of cardiac perfusion, such as quantitative gated single photon emission computed tomography (SPECT), have reported either little improvement (29) or no improvements in either resting or treadmill exercise stress myocardial perfusion in patients with CAD after EECP treatment (19) . In fact, SPECT imaging of target ischemic myocardial segments revealed small, but significant, declines in myocardial blood flow after exercise stress at 1 month after EECP treatment in some regions of the heart (19) . Notwithstanding the negative SPECT imaging results, all EECP studies to date uniformly report increased exercise time to angina symptoms, and 85% of study subjects have an improvement in angina class (2, 29) . These clinical benefits are in excess of any documented changes in myocardial perfusion, as measured by radionuclide imaging, and support the argument that cardiac angiogenesis cannot be the sole mechanism responsible for EECP-induced symptom reductions.
THERAPEUTIC TARGET OF EECP: THE PERIPHERAL HYPOTHESIS
Several years ago, Zhang and coworkers (35) used color Doppler imaging in a porcine EECP model and found that brachial artery blood flow velocity increased by 132% (59 vs 24 cm/second; P G 0.001) and brachial artery wall shear stress increased by greater than 200% (49 vs 23 dyne/cm 2 , P G 0.001) during lower body compression of EECP pneumatic cuffs. These findings are intriguing and of great biological importance because blood flow<induced endothelial shear stress (ESS) is the major physiological stimulus that maintains vascular endothelial function (9) . Currently, however, there are few therapeutic interventions that could create episodic increases in arterial shear stress in humans, although selected modes of exercise are known to create pulsatile, hemodynamic shear forces and improve endothelial function (10) . The remainder of this review summarizes support for our hypothesis that peripheral arterial function may be the therapeutic target for EECP in patients with symptomatic CAD.
ACUTE EFFECTS OF EECP ON ENDOTHELIAL FUNCTION
We recently sought to confirm the findings of Zhang and coworkers (35) , observed in a porcine EECP model, by designing the first study to record acute EECP-induced endothelial shear stress in both femoral and brachial arteries during ''real-time'' EECP using high-definition ultrasound images and color Doppler spectrum in humans. Moreover, we desired to go a step further and assess the acute effects of EECP on endothelial function in both femoral and brachial arteries using the flow-mediated dilation (FMD) technique immediately after a single session of EECP (11) . Eighteen healthy, young men (25 T 4 yr) were assigned randomly to either one 45-min session of EECP or sham EECP. We observed that acute EECP treatment produces two opposite blood flow patterns: antegrade flow in the brachial artery and retrograde flow in the femoral artery. During EECP, shear stress in the brachial artery was increased by 75% (29.0 T 6.6 vs 16.6 T 4.1 dynesIcm j2 ; P G 0.05), and proximal femoral artery shear stress was increased by 402% (j19.1 T 5.1 vs j3.8 T 0.3 dynesIcm j2 ; P G 0.01) when compared with sham. Both brachial artery FMD (from 7.0 to 10.6%; P G 0.05) and femoral artery FMD (from 7.8 to 13.1%; P G 0.05) were increased significantly after a single session of EECP, compared with baseline (11) . These data suggested to us that dramatic increases in shear stress created by EECP, whether antegrade in the arms or retrograde in the legs, improve endothelium-dependent arterial vasodilation in muscular conduit arteries. However, this study was not designed to assess whether changes in conduit artery function are accompanied by commensurate changes in the microcirculation. The significant increases in pulsatile and oscillatory flow during EECP treatment may provide a form of ''massage'' on the endothelium and improve its function. That is, each session of EECP may be thought of as providing a direct dose of vascular medicine.
CHRONIC EFFECTS OF EECP ON ENDOTHELIAL FUNCTION
We conducted the first randomized sham-controlled investigation to determine the chronic effects of EECP (i.e., episodic changes in shear stress, as delivered during repeated bouts of EECP) on endothelial function in peripheral muscular conduit arteries and commensurate changes in plasma levels of endothelial-derived vasoactive agents, proinflammatory cytokines, markers of lipid peroxidation, and antioxidant capacity (5) . Forty-two consecutive patients with refractory angina were randomized in a 2:1 manner into either EECP treatment groups or sham-EECP control groups. Most of the subjects were men (81%), and all had a long history of CAD and interventions and were not candidates for further revascularization therapy. All vasodilator drugs were discontinued 12 h before laboratory testing. Patients followed the National Institutes of Health low-nitrate diet guidelines a minimum of 48 h before each blood draw.
EECP and Flow-Mediated Dilation
At study entry, resting diameter and FMD (absolute diameter and $%) of the brachial and femoral arteries did not differ between groups. EECP treatment improved absolute brachial artery FMD by 51% ( Fig. 2A ) and percent change in dilation (Fig. 2C ). EECP also improved absolute femoral artery FMD by 39% ( Fig. 2B ) and percentage change in dilation ( Fig. 2D ). No changes in brachial or femoral FMD occurred in the sham group.
EECP and Endothelial-Derived Vasoactive Agents
Endothelial dysfunction in patients with CAD is manifest by either decreased bioavailability of paracrine vasodilators including nitric oxide and 6-keto-PGF 1> , the major metabolite of prostacyclin, or an increased production of the potent vasoconstrictor endothelin-1 (ET-1) and/or resistance of vascular smooth muscle to nitric oxide. Thirty-five sessions of EECP increased plasma levels of nitrate and nitrite (NOx), the stable metabolites of nitric oxide, by 36%, whereas ET-1 levels concurrently were decreased by 25% ( Fig. 3) . EECPinduced increases in pulsatile endothelial shear stress are the putative mechanism responsible for the observed changes in NOx and ET-1. It is well documented that low endothelial shear upregulates ET-1 and downregulates endothelial nitric oxide synthase (eNOS) (9) . ET-1 values after EECP treatment compare favorably with reference values (1 to 1.5 pgIml Y1 ) in normal healthy humans (16) . Previously, Zhang and coworkers (35) reported that EECP increased the expression of eNOS in hypercholesterolemic pigs, and small uncontrolled studies also have reported increased plasma NOx levels in patients with CAD after EECP (1). Akhtar et al. (1) found that NOx significantly remained above baseline (+12%), and ET-1 significantly remained below baseline (j11%) at 3 months after completion of EECP treatment in patients with CAD.
EECP and Proinflammatory Cytokines and Endothelial Adhesion Molecules
Endothelial function is affected adversely by inflammation, and extensive evidence indicates that patients with CAD have elevated levels of proinflammatory cytokines and adhesion molecules, including tumor necrosis factor-> (TNF->), high-sensitivity C-reactive protein (hsCRP), monocyte chemoattractant protein-1 (MCP-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) (3). Moreover, patients with CAD with refractory angina symptoms have proinflammatory biomarker levels that are elevated even further (3) . Increased plasma levels of TNF->, hsCRP, and MCP-1 are known to predict future coronary events. In vitro, CRP and TNF-> also actively participate in the atherogenic process by contributing to decreased nitric oxide synthase production and increased endothelial cell activation characterized by expression of sVCAM-1 (32) . After 35 sessions of EECP treatment, we observed reductions in plasma levels of TNF-> (j16%), hsCRP (j32%), MCP-1 (j13%), and sVCAM-1 (j6%) ( Fig. 4) (5) . No changes in inflammatory cytokines or endothelial adhesion molecules were observed in the sham group.
The anti-inflammatory effects of EECP clinically may be relevant with regard to decreasing the risk for future cardiovascular events in this patient population. For instance, sVCAM-1 levels above È1130 ngIml Y1 are associated with increased ischemic events and mortality in patients with CAD (24) . In our largest study examining the anti-inflammatory effects of EECP, 6 of 28 patients in the intervention group had baseline sVCAM-1 greater than 1130 ngIml Y1 . After EECP, only 1 of 28 patients had sVCAM-1 values greater than 1130 ngIml Y1 (5) . Similarly, EECP shifted mean CRP values from the high-risk (93 mgIL Y1 ) to the moderate-risk category (1 to 3 mgIL Y1 ) (26) . Despite significant reductions, TNF-> levels after EECP remained high and approximated the 95th percentile of healthy control values (27) . Increased bioavailability of nitric oxide after EECP therapy is the likely mechanism responsible for reduced plasma inflammatory markers. Nitric oxide serves an anti-inflammatory role by inhibiting the expression of MCP-1 and reducing VCAM-1 expression (12) .
EECP and Lipid Peroxidation and Antioxidant Capacity
F2-isoprostanes are a class of prostaglandin-like compounds that are produced by free radical-mediated lipid peroxidation of arachidonic acid, independent of cyclooxygenase. One of these isoprostanes, 8-isoprostaglandin F 2> (8-iso-PGF 2> ), is a good plasma marker to assess oxidative stress (20) . Moreover, 8-iso-PGF 2> is a potent vasoconstrictor and an independent risk factor associated with CAD (34) . We observed a 21% decrease in plasma levels of 8-iso-PGF 2a after 35 1-hr sessions of EECP. The mechanisms responsible for decreased 8-iso-PGF 2a are unclear. EECP did not change activity levels of the extracellular antioxidant enzyme superoxide dismutase, and changes in oxidant production by predominate enzyme systems, such as NADPH oxidases, xanthine oxidase, and eNOS, were not measured in that study. However, nitric oxide has been shown to have antioxidative properties, and our observed 36% increase in plasma NOx after EECP could suppress oxidative stress.
We also were the first to measure the effects of EECP on plasma levels of asymmetric dimethylarginine (ADMA), the major endogenous competitive inhibitor of nitric oxide synthase (5) . ADMA can be increased up to 10-fold greater than normal in patients with CAD (30) . We observed a 28% reduction in plasma ADMA levels after 35 one-hour sessions of EECP. This finding is similar to what has been reported after exercise training in patients with CAD (25) . ADMA contributes to endothelial dysfunction by displacing the substrate L-arginine from the catalytic site of nitric oxide synthase, thus inhibiting nitric oxide formation and reducing nitric oxide bioavailability. Oxidative stress is a key modulator of ADMA levels (30) , suggesting that our observed 21% reduction in the marker of oxidative stress (8-iso-PGF 2> ) may have led to decreased levels of ADMA.
CHRONIC EFFECTS OF EECP ON ARTERIAL STIFFNESS
Arterial stiffness increasingly is recognized as a surrogate end point for cardiovascular disease. Central aortic stiffness, expressed as aortic pulse wave velocity (PWV), is a strong predictor of future cardiovascular events and all-cause mortality based on the results of individual studies (33) . In contrast to widely held, but largely unsubstantiated beliefs, abnormalities in arterial stiffness are modifiable. Elastic conduit artery (aorta) function is passively modifiable by lowering mean arterial pressure and reflection. Muscular conduit artery (brachial, femoral) properties are actively modifiable by changes in endothelial function and/or vascular smooth muscle.
We conducted the first randomized sham-controlled study to test the hypothesis that EECP treatment would decrease both central and peripheral arterial stiffness in patients with CAD, as determined by PWV techniques (6) . Pressure waveforms were recorded at the following three sets of sites sequentially V carotid-radial (arm), carotid-femoral (aorta), and femoral-dorsalis pedis (leg) V using a SphygmoCor Pulse Wave Velocity Vx system and SCOR-2000 6.31 software (AtCor Medical). Our results demonstrated that central aortic stiffness is decreased after short-and long-term EECP treatment (17 and 35 sessions, respectively) ( Fig. 5 ). EECP treatment also decreased peripheral arterial stiffness in the upper (arm) and lower (leg) body, thus suggesting that improvements in arterial stiffness are not limited to vascular regions directly exposed to external mechanical compression ( Fig. 5 ).
Stiffness of a vessel commonly is thought to be controlled by the distending (mean arterial) pressure and structural elements within the vessel wall. Changes in distending pressure can impact stiffness in large elastic arteries as well as muscular arteries. Therefore, the possibility exists that the changes in arterial stiffness (i.e., PWV) after EECP are caused by the passive effect of a decreased mean arterial pressure (MAP). After controlling for change in MAP, change in carotid-femoral PWV in the EECP group remained highly significant (P G 0.001). However, changes in carotid-radial (P = 0.15) and femoraldorsalis pedis (P = 0.08) PWV after treatment were no longer significant. This suggests that the improvements in central PWV (i.e., aorta) were independent of blood pressure changes, whereas decreases in peripheral PWV after EECP partly were due to a decrease in pressure.
We reasoned that the decreases in regional and systemic arterial stiffness after EECP may be explained by the improvements in endothelial function reported above. EECP has been shown by us and others to have a dose-related sustained effect in stimulating endothelial production of nitric oxide and de-creasing the release of the potent vasoconstrictor ET-1 (1, 5) . EECP-induced improvements in endothelial function likely decreases smooth muscle tone and arterial stiffness and consequently alters wave reflection from peripheral arteries. It also is possible that improvements in the capacitive or reservoir function of the aorta after EECP contribute to the improved aortic wave characteristics (9) . Aortic reservoir pressure, a major contributor to central augmented pressure and the timing and amplitude of reflected pressure waves, increases with aging as a result of decreasing compliance and increasing impedance to outflow in the aorta.
LEFT VENTRICULAR WORK AND INDEXES OF MYOCARDIAL OXYGEN DEMAND
EECP-induced improvements in peripheral endothelial function and arterial stiffness should cause a significant reduction in LV afterload and, consequently, a reduction in myocardial oxygen demand. We have performed two studies investigating whether these EECP-induced reductions in LV afterload are indeed associated with improvement in indexes of myocardial oxygen demand in patients with CAD with chronic ischemic symptoms (6, 21) .
In our laboratory, indexes of LV afterload and myocardial oxygen demand are derived noninvasively from the assessment of arterial wave reflection characteristics. This technique was well described previously (22) and shown to estimate central arterial pressures to 0.2 T 3.8 mm Hg error or less (8) . A typical aortic pressure waveform synthesized from radial pressure waves using applanation tonometry and the generalized transfer function is shown in Figure 6 . The central aortic pressure wave is composed of a forward traveling wave, generated by LV ejection and a reflected wave that is returning to the ascending aorta from the periphery. When the reflected wave returns during systole, as seen in Figure 6 , the aortic pressure is augmented, and, therefore, the LV must generate enough energy to overcome this added boost in pressure and opposition to emptying. This energy is wasted because it does not contribute to blood flow production and can be estimated as [(ED-$t p )I (CSBP-P i ) P/4I1.3332], where 1.3332 is the conversion factor for mm Hg per second to dynesIseconds per square centimeter. In our initial open-label uncontrolled study, we demonstrated that 34 sessions of EECP resulted in a significant decrease in aortic augmentation index (from 18 T 9% to 12 T 8%; P G 0.01), wasted left ventricular pressure energy (LVE w ) (from 1,560 T 162 to 1,360 T 166 dynesIsecIcm j2 ; P G 0.001) and an increase in round-trip travel time of pressure wave from the heart to the periphery and back (from 68 T 8 to 74 T 6 ms; P G 0.001) in patients with CAD with refractory angina (21) . We have expanded recently on our pilot research by conducting the first randomized sham-controlled study investigating the effects of EECP treatment on indexes of myocardial oxygen demand in patients with CAD with chronic angina symptoms refractory to conventional medical and revascularization treatment (6) . Pulse wave analysis results demonstrated a progressive decrease in aortic augmentation index after 17 (25.8 T 2.7%) and 35 (23.3 T 2.7%) sessions of EECP compared with baseline (29.1 T 2.3%, P e 0.01; Fig. 7 ). Likewise, there was a progressive increase in round-trip travel time of pressure wave from the heart to the periphery and back after 17 (143 T 2 ms) and 35 (145 T 2 ms) sessions of EECP compared with baseline (140 T 2 ms, P G 0.01). Aortic systolic tension-time index (AsTTI) also was decreased after 35 sessions of EECP (from 2,287 T 93 to 2,071 T 73 mmHgIsImin j1 ; P e 0.05). The difference in AsTTI resulted in a significantly higher subendocardial viability ratio (from 147 T 6 to 172 T 8; P e 0.01) after EECP treatment. In turn, these vascular adaptations lead to a substantial decrease in LVE w after 35 sessions of EECP compared with pretreatment values (from 2,167 T 372 to 1,598 T 233 dynesIsec cm -2 , P G 0.01; Fig. 7 ). These modifications in wave reflection characteristics and indexes of myocardial oxygen demand were accompanied by a 14% increase in peak oxygen consumption (V O 2peak ), improvements in Canadian Cardiovascular Society angina classification from 3.1 to 1.2 (mean), decreases in daily angina episodes by È72%, and daily nitrate usage by 81% (6) .
SUMMARY AND CONCLUSIONS
Only through identification of the specific mechanisms responsible for the anti-ischemic clinical benefits of EECP will this treatment option receive acceptance by the medical community for the treatment of symptomatic CAD. There are inadequate data to support the hypothesis that EECP increases myocardial perfusion and oxygen supply. In this review, the authors have proposed an alternative hypothesis and presented novel data from studies that investigated peripheral vascular adaptations to EECP. In aggregate, results support the hypothesis that EECP improves peripheral arterial function, which serves to reduce myocardial oxygen demand. Our hypothesis is further supported by novel neurohormonal evidence that EECP markedly increases plasma NOx and 6-keto-PGF 1> , and simultaneously decreases ET-1, 8-iso-PGF 2> , and the pro-inflammatory markers TNF->, hsCRP, MCP-1, and sVCAM-1.
As suggested previously by others (15) , EECP treatment seems to exert a ''training'' effect. Indeed, the results from our Figure 6 . A typical central aortic pressure waveform synthesized from the radial artery pressure waveform using applanation tonometry, with superimposed waveform of aortic blood flow. The dotted line is representative of the theoretical aortic pressure waveform independent of wave reflection. Augmentation index is the ratio of augmented pressure (CSBPYPi) and central aortic pulse pressure (CSBPYCDBP). Wasted left ventricular pressure energy (LVE w ) is defined as the portion of area under the pulse pressure curve attributed to amplitude and duration of wave reflection where, although there is an increased systolic pressure, blood flow through the aorta decreases. LVE w , expressed in dynesIseconds per square centimeter, is related directly to augmented pressure (calculated as CSBPYPi) and to the time duration of the reflected aortic pressure wave, ($t r ). $tp, time to arrival of the reflected pressure wave; CDBP, central aortic diastolic blood pressure; CSBP, central aortic systolic blood pressure; ED, ejection duration; ESP, end systolic pressure; P i , pressure at the first inflection point marking the onset of reflected aortic pressure wave return from the periphery. (Reprinted from (17) . Copyright * 2011 Nature Publishing. Used with permission.) Figure 7 . Changes in aortic augmentation index (AI x ) (A) and wasted left ventricular pressure energy (LVEw) (B) before (PRE) and after 17 (MID) and studies with EECP treatment (5Y7,11,21) are similar to those reported by others as a result of exercise training (10) produced by running, which increases blood flow and wall shear stress in the muscular arteries of the legs. EECP creates significant increases in shear stimulus via pulsatile retrograde flow and antegrade flow in the femoral and brachial arteries, respectively. Moreover, we calculate that with a resting heart rate of 60 beats per minute, 35 one-hour EECP sessions cause approximately 150,000 hyperemic episodes (stimuli) in the arteries of both the lower and upper extremities. These chronic maneuvers increase release of nitric oxide from endothelial cells and thus cause vasodilation, with a delayed return of the reflected wave from the lower body to the heart and reduced LVE w .
